

CR Beer (291 HK)

1H22 beat on better cost efficiency; our top pick over 2H22

- **1H22 beat.** Recurring EBIT came in at RMB5.2bn, up 17% YoY, above our estimates. Given 7% revenue growth (to RMB21bn) and a stable GPM YoY (42.3%), growth in recurring EBIT looks to be mainly underpinned by a 3.4pp lower SG&A. We attribute this to a higher operation efficiency and a more optimized resources allocation, when the company scaled back its investment pace and advertising expense over the challenging 1H.
- **Major financial indicators are in line with us.** Shipment/ ASP/ GPM all came in in line with us/ market expectation. Of note, a 7.7% ASP uptick not only neutralized a 1% decline in shipment but also mitigated higher raw material costs and stabilized GPM. Premium/ sub-premium shipment grew 10% YoY, and was consistent to our NDR takeaway.
- **Management call highlights:**
 - i) The 10% volume growth of premium/ sub-premium SKUs (18.1% volume share from 16.4% in 1H21) was mainly driven by Heineken (+30% YoY), while Snow Draft/ SuperX grew at LSD YoY in 1H, being negatively affected by a high exposure to on-trade channels (c.70-80% of their sales volume). These, though, have been recovering quickly since Jun and would be back to HSD volume growth in 2H.
 - ii) Overall sales volume recovery has been well on track since Jun, helped by hot weather across many regions in China, with YTD volume growth back to positive in Jul and MTD growth to high teens in Aug.
 - iii) Heineken/ SnowDraft/ SuperX/ Laoxue are the main key brands to promote in 2H22, which could drive 2H22/ 2022E volume growth to be at LSD. Management remained positive on the premiumization trend in China's beer market in the next 3-5 years, and turned marginally more optimistic on raw material cost pressure by revising down annual increment to RMB1.2-1.3bn, from previously RMB1.5-1.6bn.
- **Earnings revision and valuation.** While 1H typically contributes 85%+ of full year NI, and taking into account a strong summer sales momentum, we consider CR Beer's earnings risk as rather limited for 2H. We raised our 2022/23E recurring EBIT by 8.4%/ 8.9%, which lead to 9.4%/ 8.6% increase in NI over the same period. Our new TP is based on 27.0x (from 28.0x) mid-23E EV/ EBITDA which represents +1sd above mean since 2018.

Earnings summary

(YE 31 Dec)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue (RMB mn)	31,448	33,387	34,501	36,436	39,251
YoY growth (%)	(5.2)	6.2	3.3	5.6	7.7
Net income (RMB mn)	2,094	4,587	4,190	4,650	5,267
EPS (RMB)	0.8	1.1	1.3	1.4	1.6
YoY growth (%)	NM	37.0	17.0	11.0	13.3
Consensus EPS (RMB)	NA	NA	1.3	1.6	1.9
P/E (x)	NA	NA	36.1	32.6	28.7
P/B (x)	NA	NA	6.0	5.3	4.8
Div yield (%)	NA	NA	1.1	1.2	1.4
ROE (%)	12.8	15.7	16.8	17.3	17.5
Net gearing (%)	Net cash	Net cash	Net cash	Net cash	Net cash

Source: Company data, Bloomberg, CMBIGM estimates

BUY (maintain)

Target Price **HK\$72.4**
 (Previous TP **HK\$71.0**)
 Up/Downside **+29.3%**
 Current Price **HK\$56.0**

China Consumer Staples

Joseph Wong
 (852) 3900 0838
 josephwong@cmbi.com.hk

Zheng Xiaohui
 (852) 3900 0838
 zhengxiaohui@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	181,674
Avg 3 mths t/o (HK\$ mn)	473.7
52w High/Low (HK\$)	68.7/ 38.4
Total Issued Shares (mn)	3,244

Source: Wind

Shareholding Structure

CRH Beer	51.7%
Morgan Stanley	4.7%
HHLR	4.1%


Source: Wind

Share Performance

	Absolute	Relative
1-mth	7.0%	10.2%
3-mth	22.8%	28.8%
6-mth	-11.9%	13.5%

Source: Wind

12-mth Price Performance



Source: Wind

Auditor: Deloitte

Related Reports

1. [【行业研究】实地调研专题系列之二 - 食品饮料经销商渠道调研情况梳理与投资观点 - 2 Aug 2022](#)
2. [【行业研究】日常消费板块 - 商超渠道调研情况梳理与投资观点 - 22 Jul 2022](#)

- **Our channel check takeaway.** Beer witnessed a strong demand recovery in July/ August, mainly driven by, in our view, re-opening of on-trade channels and a hot summer. On-trade channels have been gradually recovering since Jun, when major Chinese cities such as Shanghai and Beijing started to marginally ease their lockdown policy, and which would have recovered to c.60-70% re-opening rate so far, with barbecue restaurants and large food stalls to c.80-90%. Other than that, we note also that products priced RMB10+ have resumed DD YoY growth from Jun-to-date, taking shares from those priced RMB5-10 (HSD growth) and those priced <RMB5 (negative growth). Overall channel inventory is c.10-15 days higher than average but looks to be normal during peak sales season.

Figure 1: Earnings revision

RMB mn	New			Old			Diff (%)		
	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenue	34,501	36,436	39,251	34,494	35,849	38,426	0.0%	1.6%	2.1%
Gross Profit	13,510	14,402	15,881	13,507	14,568	16,204	0.0%	-1.1%	-2.0%
Recurring EBIT	5,450	6,072	6,908	5,027	5,575	6,566	8.4%	8.9%	5.2%
Net profit	4,190	4,650	5,267	3,832	4,281	5,042	9.4%	8.6%	4.5%
Gross Margin	39.2%	39.5%	40.5%	39.2%	40.6%	42.2%	0ppt	-1.1ppt	-1.7ppt
EBIT Margin	15.8%	16.7%	17.6%	14.6%	15.6%	17.1%	1.2ppt	1.1ppt	0.5ppt
Net margin	12.1%	12.8%	13.4%	11.1%	11.9%	13.1%	1.0ppt	0.8ppt	0.3ppt


Source: Company data, CMBIGM estimates

Figure 2: CMBIGM estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenue	34,501	36,436	39,251	36,291	39,108	42,072	-4.9%	-6.8%	-6.7%
Gross Profit	13,510	14,402	15,881	14,549	16,448	18,371	-7.1%	-12.4%	-13.6%
Recurring EBIT	5,450	6,072	6,908	5,067	6,379	7,798	7.6%	-4.8%	-11.4%
Net profit	4,190	4,650	5,267	4,052	5,147	6,381	3.4%	-9.7%	-17.5%
Gross Margin	39.2%	39.5%	40.5%	40.1%	42.1%	43.7%	-0.9ppt	-2.5ppt	-3.2ppt
EBITs margin	15.8%	16.7%	17.6%	14.0%	16.3%	18.5%	1.8ppt	0.4ppt	-0.9ppt
Net margin	12.1%	12.8%	13.4%	11.2%	13.2%	15.2%	1.0ppt	-0.4ppt	-1.7ppt


Source: Company data, CMBIGM estimate

Figure 3: 12M forward EV/EBITDA chart



Source: Bloomberg, CMBIS estimates

Figure 4: Trailing P/B chart



Source: Bloomberg, CMBIS estimates

Financial Summary

Income statement

YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue	31,448	33,387	34,501	36,436	39,251
Premium & Super premium	7,330	9,585	10,940	13,300	16,662
Sub-premium	24,118	23,802	23,561	23,136	22,590
Gross profits	12,075	13,074	13,510	14,402	15,881
D&A	(1,553)	(1,641)	(1,643)	(1,700)	(1,753)
Selling expense	(6,123)	(6,743)	(6,210)	(6,376)	(6,869)
Administration expenses	(4,419)	(3,619)	(2,760)	(2,915)	(3,140)
Other operating expenses	1,546	3,300	910	961	1,035
Others	1,553	1,641	1,643	1,700	1,753
EBIT	3,079	6,012	5,450	6,072	6,908
EBITDA	4,632	7,653	7,093	7,772	8,661
Finance costs, net	80	224	224	224	224
Non-operating	(150)	(21)	-	-	-
Pre-tax profit	3,009	6,215	5,674	6,296	7,132
Income tax	(915)	(1,625)	(1,484)	(1,646)	(1,865)
Less: Minority interests	-	(3)	-	-	-
Net profits (reported)	2,094	4,587	4,190	4,650	5,267

Cash flow summary

YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Net income	2,094	4,587	4,190	4,650	5,267
D&A	1,553	1,641	1,643	1,700	1,753
Change in working capital	(1,165)	178	(2,242)	(2,904)	(3,866)
Others	1,998	(1,411)	(500)	(300)	-
Net cash fr. operating act.	4,480	4,995	3,092	3,146	3,154
Capex & investments	(1,047)	(1,471)	(1,397)	(1,328)	(1,261)
Acquisition	-	-	-	-	-
Others	(23)	(1,279)	-	-	-
Net cash fr. investing act.	(1,070)	(2,750)	(1,397)	(1,328)	(1,261)
Equity raised	-	-	-	-	-
Change of Debts	1,469	-	-	-	-
Dividend paid	(561)	(1,281)	(1,836)	(1,676)	(1,860)
Others	(2,105)	(85)	-	-	-
Net cash fr. financing act.	(1,197)	(1,366)	(1,836)	(1,676)	(1,860)
Net change in cash	2,213	879	(142)	142	33
Cash at the beginning of the	2,340	4,538	5,376	5,234	5,377
Exchange difference	(15)	(41)	-	-	-
Cash at the end of the year	4,538	5,376	5,234	5,377	5,410
Less: pledged cash	-	-	-	-	-

Balance sheet

YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Non-current assets	30,398	35,156	33,529	33,157	32,665
PP&E/Fixed assets	17,781	17,096	16,870	16,518	16,046
Goodwill	9,326	9,250	9,250	9,250	9,250
Deferred tax assets	2,858	3,368	3,368	3,368	3,368
Other non-current assets	433	5,442	4,041	4,021	4,001
Current assets	13,377	15,897	16,543	17,241	18,022
Cash	4,538	5,376	5,234	5,377	5,410
Account receivable	2,378	3,436	3,781	3,993	4,302
Taxation recoverable	6,014	6,458	6,901	7,244	7,683
Other current assets	447	627	627	627	627
Current liabilities	19,572	21,170	19,716	17,367	14,249
Borrowings	-	-	-	-	-
Account payables	19,327	21,007	19,553	17,204	14,086
Other payables	162	92	92	92	92
Lease liabilities	83	71	71	71	71
Non-current liabilities	2,929	5,394	4,894	4,594	4,594
Borrowings	-	-	-	-	-
Deferred tax liabilities	788	1,955	1,955	1,955	1,955
Other non-current liabilities	2,141	3,439	2,939	2,639	2,639
Minority Interest	57	57	57	57	57
Total net assets	21,274	24,489	25,462	28,436	31,843
Shareholders' equity	21,217	24,432	25,405	28,379	31,786

Key ratios

YE 31 Dec	FY20A	FY21A	FY22E	FY23E	FY24E
Sales mix (%)					
Premium & Super premium	23.3	28.7	31.7	36.5	42.4
Sub-premium	76.7	71.3	68.3	63.5	57.6
P&L ratios (%)					
Gross margin	38.4	39.2	39.2	39.5	40.5
Operating margin	9.8	18.0	15.8	16.7	17.6
Pre-tax margin	9.6	18.6	16.4	17.3	18.2
Net margin	6.7	13.7	12.1	12.8	13.4
Effective tax rate	(30.4)	(26.1)	(26.1)	(26.1)	(26.1)
Balance sheet analysis					
Current ratio (x)	0.3	0.3	0.3	0.3	0.3
Net receivable days	28	38	40	40	40
Net payable days	364	377	340	285	220
Inventory turnover days	113	116	120	120	120
Net debt to equity (%)	Net	Net	Net	Net	Net
	cash	cash	cash	cash	cash
Returns (%)					
ROE	12.8	15.7	16.8	17.3	17.5
ROA	4.8	9.0	8.4	9.2	10.4
Dividend yield	N.A.	N.A.	1.1	1.2	1.4
Per share					
EPS - recurring (RMB)	0.8	1.1	1.3	1.4	1.6
DPS (RMB)	0.3	0.6	0.5	0.6	0.6
BVPS (RMB)	6.5	7.5	7.8	8.7	9.8

Source: Company data, CMBIGM estimates

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY	: Stock with potential return of over 15% over next 12 months
HOLD	: Stock with potential return of +15% to -10% over next 12 months
SELL	: Stock with potential loss of over 10% over next 12 months
NOT RATED	: Stock is not rated by CMBIGM

OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBIGMG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBIGMG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBIGMG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBIGMG at +65 6350 4400 for matters arising from, or in connection with the report.